Cargando…
Novel and emerging therapies for B cell lymphoma
Lymphomas are a heterogeneous group of lymphoproliferative disorders, with unique clinical and biological characteristics that exhibit variable response to therapy. Advances in chemo-immunotherapy have improved outcomes in a number of lymphoma subtypes; however, the prognosis for many patients with...
Autores principales: | Ayyappan, Sabarish, Maddocks, Kami |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659277/ https://www.ncbi.nlm.nih.gov/pubmed/31345247 http://dx.doi.org/10.1186/s13045-019-0752-3 |
Ejemplares similares
-
Correction to: Novel and emerging therapies for B cell lymphoma
por: Ayyappan, Sabarish, et al.
Publicado: (2021) -
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
por: Sawalha, Yazeed, et al.
Publicado: (2020) -
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
por: Bond, David A, et al.
Publicado: (2021) -
Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023) -
Novel Therapies for Aggressive B-Cell Lymphoma
por: Foon, Kenneth A., et al.
Publicado: (2012)